Evolus delivered a strong Q4 with $90.3 million in revenue, up 14% year-over-year, and achieved GAAP operating income of $4.2 million. The company successfully expanded its injectable portfolio with Evolysse and demonstrated significant operating leverage following expense reduction measures taken earlier in the year.

Evolus delivered strong third-quarter results with total net revenue of $69.0 million, a 13% increase year-over-year, driven by robust global Jeuveau® sales and a successful debut of Evolysse™. The company demonstrated sequential growth that outperformed typical seasonal trends and made significant strides in expense management, positioning itself for positive non-GAAP operating income in Q4 2025 and sustainable annual profitability starting in 2026.

Evolus reported global net revenue of $69.4 million for Q2 2025, a 4% increase from Q2 2024, driven by the successful launch of Evolysse™ and strong international market performance, despite a softened U.S. toxin demand. The company also took decisive action to optimize its cost structure, aiming for meaningful profitability in Q4 2025.

Evolus reported global net revenue of $68.5 million for Q1 2025, a 15.5% increase year-over-year, driven by strong Jeuveau® demand and market share gains. The company launched Evolysse™ in the U.S. in Q2 and remains on track to achieve positive non-GAAP operating income for the full year 2025.

Evolus achieved a record fourth-quarter revenue of $79.0 million, representing a 30% increase year-over-year. The company reported a GAAP operating loss of $2.3 million, with a positive non-GAAP operating income of $6.7 million. Cash and cash equivalents increased to $87.0 million, reflecting strong sales growth and prudent expense management.

Evolus reported a 22% increase in total net revenues for Q3 2024, reaching $61.1 million, driven by higher volumes of Jeuveau®. The company narrowed its full-year revenue guidance to $260 million to $266 million and reaffirmed its expectation of non-GAAP profitability in Q4 2024 and full year 2025. Evolus also received approval for Estyme® in the European Union and anticipates the launch of Evolysse™ in the U.S. by September 2025.

Evolus reported a 36% increase in total net revenue for Q2 2024, reaching $66.9 million. The company achieved its first ever quarter of profitability with positive non-GAAP operating income of $1.1 million. Full-year 2024 net revenue guidance was raised to $260 million to $270 million.

Evolus reported strong Q1 2024 results with net revenue increasing by 42% to $59.3 million compared to Q1 2023. The company added over 700 new customer accounts and saw growth in its Evolus Rewards consumer loyalty program. Evolus reaffirms its full-year 2024 net revenue guidance of $255 million to $265 million and remains on track to achieve its projected total net revenue goal of at least $700 million by 2028.

Evolus reported a record fourth quarter global net revenue of $61.0 million, representing a 40% increase compared to the same period last year. The company also generated $0.8 million of cash from operating activities and significantly reduced its non-GAAP operating loss to $3.7 million.

Evolus reported a record third quarter with net revenue of $50 million, a 48% increase from Q3 2022. The company is raising its full-year 2023 revenue guidance to $194 to $198 million. They are progressing towards profitability, with operating cash use at $0.9 million for the quarter.

Evolus reported a strong second quarter with net revenue increasing 33% year-over-year to $49.3 million. The company raised its full-year 2023 net revenue guidance to $185 to $195 million and is on track to achieving sustained profitability with existing cash.

Evolus reported a 23% increase in revenue to $41.7 million for Q1 2023 compared to Q1 2022. The company reaffirms its full-year 2023 net revenue guidance of $180 to $190 million and raises its 2028 revenue outlook from $500 million to $700 million due to the addition of the Evolysse™ dermal filler line.

Evolus reported strong Q4 2022 results, with net revenue reaching an all-time high of $43.6 million, a 26% increase from Q4 2021. The company reaffirmed its full-year 2023 net revenue guidance of $180 to $190 million and expects positive non-GAAP operating income in Q4 2023.

Evolus reported a 27% increase in sales to $33.9 million in Q3 2022, driven by higher volumes of Jeuveau and the success of the 'Switch Your Tox' promotion. The company is reiterating its full-year 2022 net revenue guidance at the top end of $143 to $150 million range and lowered non-GAAP operating expense guidance to the lower half of the range. Evolus expects its cash position of $65.6 million to fund the company to breakeven.

Evolus reported a 42% increase in net revenue to $37.2 million compared to Q2 2021. The company reaffirms full-year 2022 net revenue guidance of upper end of $143 to $150 Million. Evolus expects its existing cash balance will fund current operations through cash flow breakeven.

Evolus reported a strong first quarter in 2022, with net revenue increasing by 177% to $33.9 million compared to the first quarter of 2021. The company is now guiding to the upper end of its full-year 2022 net revenue guidance of $143 to $150 million. Evolus reiterates its full-year non-GAAP operating expense guidance and maintains a strong cash position of $106.7 million, which is expected to fund the company to breakeven.

Evolus reported a strong fourth quarter and full-year 2021, with Q4 net revenue increasing by 68% to $34.7 million compared to Q4 2020. The company's full-year net revenue grew by 76% to $99.7 million. Evolus is confident in its 2022 net revenue guidance of $143 million to $150 million.

Evolus reported a strong third quarter with record sales of Jeuveau®, driven by increased volumes and successful co-branded marketing campaigns. U.S. net revenues increased by 58% year-over-year to $26.7 million. The company is also investing in a Phase II program to study an 'extra strength' dose for extended duration of Jeuveau®.

Evolus reported a record level of sales in Q2 2021, with net revenues increasing by 235% year-over-year to $26.1 million. The company exceeded its annualized revenue run rate goal of $100 million and had a strong cash position of $131.7 million at quarter-end. Evolus is on track for a European launch in early 2022.

Evolus reported Q4 2020 net revenue of $20.6 million, the highest since the launch of Jeuveau. The company also successfully transformed its business by settling the ITC case and related litigation, eliminating $127 million of debt and payment obligations, and strengthening its cash position.

Evolus reported a 34% increase in net revenue compared to Q3 2019, driven by strong Jeuveau® sales. The company also reduced operating expenses by 38%.

Evolus reported a significant increase in net revenue for Q2 2020, rising to $7.8 million from $2.3 million in Q2 2019. The company also achieved a higher gross margin and reduced both GAAP and non-GAAP operating expenses. In July 2020, Evolus closed a $40 million convertible note financing, further strengthening its financial position.

Evolus reported $10.5 million in net revenues for Q1 2020, which was primarily reduced by a $10.2 million provision for coupons. The company enacted plans to conserve cash and significantly reduce the operating expense base, including a reduction of the employee base by greater than 40%.

Evolus reported a net revenue of $19.5 million for Q4 2019, up from $13.2 million in Q3 2019, driven by increased Jeuveau® sales. The company's net loss improved to $14.5 million, and they exited the year with a strong cash position of $129.8 million.